8-K: Rezolute Completes Enrollment for Phase 3 sunRIZE Study of Ersodetug for Congenital Hyperinsulinism

Rezolute, Inc. announced the completion of enrollment for its pivotal Phase 3 sunRIZE clinical study of ersodetug for congenital hyperinsulinism, with topline results expected by the end of 2025.

Summary

• Rezolute, Inc. has completed enrollment for its Phase 3 sunRIZE clinical study of ersodetug, a treatment for congenital hyperinsulinism (cHI).
• The study enrolled a total of 63 participants, including 8 open-label and 55 double-blind participants.
• The mean age of enrolled participants is 3.4 years, ranging from 3 months to 15 years, with approximately one-third being under 2 years old.
• Baseline demographics and disease characteristics were consistent with published epidemiology for cHI, highlighting a substantial unmet medical need.
• Despite rigorous medical management, 51% of participants were hospitalized for hypoglycemia at least once in the year prior to screening.
• 29% of participants reported experiencing Level 3 hypoglycemia with acute loss of consciousness requiring third-party emergency intervention.
• Over half of participants reported 6 or more hypoglycemia events requiring rescue intervention in the 30 days prior to study entry, with 38% reporting over 10 such events.
• Preliminary observations showed a mean hypoglycemia event rate of 15 events per week (range 3-44) and a mean average daily percent time in hypoglycemia of 19% (range 5-73%).
• An independent safety data monitoring committee (DMC) completed an interim analysis and recommended continuing the study with the originally planned sample size, indicating no futility or need for sample size increase.
• Ersodetug is a fully human IgG2 monoclonal antibody designed to decrease excessive insulin action by binding to an allosteric site on the insulin receptor.
• Ersodetug has received Breakthrough Designation Therapy from the US FDA for hypoglycemia due to congenital and tumor hyperinsulinism.
• Topline safety and efficacy results from the pivotal portion of the Phase 3 sunRIZE study are anticipated by the end of 2025.

Sentiment

Score: 8

Explanation: The document reports the successful completion of enrollment for a pivotal Phase 3 study and a positive interim analysis recommendation, indicating the trial is progressing as expected towards topline results. The high unmet medical need and FDA Breakthrough Designation for the drug are strong positives. The only negative is the inherent severity of the disease, which the drug aims to address.

Positives

• Enrollment for the pivotal Phase 3 sunRIZE study is complete, moving the drug closer to potential market availability.
• An interim analysis by an independent safety data monitoring committee (DMC) recommended continuing the study as-is with the planned sample size, suggesting no major safety or futility concerns at this stage.
• Baseline characteristics of enrolled patients reinforce the high disease burden and unmet need in the congenital hyperinsulinism population, underscoring the potential market for ersodetug.
• Ersodetug has received Breakthrough Designation Therapy from the US FDA, indicating its significant potential to address a serious condition.
• The mechanism of action of ersodetug is novel and offers potential for a universal therapy for congenital and acquired forms of hyperinsulinism.
• Previous Phase 2b study (RIZE) showed dose-responsive improvements in hypoglycemia events and time, exceeding 75%, with a nearly universal response rate, providing a positive precedent for the Phase 3 study.

Negatives

• The high disease burden and severity of hypoglycemia observed at baseline, despite current standard of care, highlight the significant challenges patients face and the critical need for effective new treatments.

Risks

• The poster contains forward-looking statements, and actual results may differ materially from anticipated results.
• Important factors that may cause differences in actual results include those discussed in the company's SEC filings, including Risk Factors in Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Unblinded topline safety and efficacy results from the pivotal portion of the Phase 3 sunRIZE study are anticipated by the end of 2025. The study has completed enrollment and an interim analysis recommended continuing with the planned sample size.

Management Comments

• "Baseline demographics and disease characteristics were consistent with published epidemiology for this population. The extent of disease burden underscores the inadequacy of current SOC options which have lacked innovation for nearly half a century and highlights the substantial unmet need in the congenital HI population."
• "Notably, the magnitude of baseline hypoglycemia events and time-in-hypoglycemia observed in this study were comparable to those reported in the Phase 2b study (RIZE), reinforcing the reproducibility and severity of disease in this rare disease population."

Industry Context

The completion of enrollment for a pivotal Phase 3 study in a rare disease like congenital hyperinsulinism (cHI) is a significant milestone in the biotechnology and pharmaceutical industry. Given the lack of innovation in cHI treatments for nearly half a century and the high disease burden despite current standard of care, ersodetug has the potential to address a substantial unmet medical need. The FDA's Breakthrough Designation further underscores the perceived importance and potential impact of this therapy.

Comparison to Industry Standards

• The baseline hypoglycemia event rates (mean 15 events/week by SMBG) and time in hypoglycemia (mean 19% by CGM) observed in the sunRIZE study are comparable to those reported in Rezolute's own Phase 2b RIZE study (13 events/week and 23% time in hypoglycemia), reinforcing the consistency of disease severity in this rare patient population across trials.
• The high rates of hospitalization (51%) and severe hypoglycemia requiring emergency intervention (29%) despite current standard of care (SOC) highlight the inadequacy of existing treatments, which have seen little innovation for nearly 50 years, positioning ersodetug as a potentially transformative therapy in a field with limited options.

Stakeholder Impact

• **Patients and Caregivers:** The study's findings, if positive, could lead to a new, potentially more effective treatment for congenital hyperinsulinism, significantly improving quality of life and reducing severe hypoglycemia events.
• **Shareholders:** The successful completion of enrollment and positive interim analysis for a pivotal Phase 3 study, with topline results expected by year-end, could positively impact investor confidence and the company's share price.
• **Medical Community:** The data from the sunRIZE study will contribute valuable insights into the management of congenital hyperinsulinism and the efficacy of ersodetug, potentially influencing clinical practice.

Next Steps

• Anticipated availability of unblinded topline safety and efficacy results for the pivotal portion of the Phase 3 sunRIZE study by the end of 2025.
• Participants completing the pivotal treatment period are eligible for rollover into a longer-term open-label extension.

Key Dates

Recommendation

Keywords

Rezolute, Ersodetug, RZ358, Congenital Hyperinsulinism, cHI, Phase 3 Clinical Study, sunRIZE, Hypoglycemia, Clinical Trial, Rare Disease, FDA Breakthrough Designation, Biotechnology, Pharmaceuticals